ClinicalTrials.gg
Not yet recruitingNCT07230145Updated Nov 17, 2025

A Trial of SHR-4658 in Healthy Volunteers or Volunteers With Elevated Blood Pressure

A Phase 1 interventional study of SHR-4658 Injection. and SHR-4658 Placebo Injection in Heart Failure, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. — 5 open to participants now, 7 under way, none of them phase 3. Heart Failure · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
7th of 10
48 · median 69
Started
2025
with 2 others
Phase 1
6 of 10
3 open now
Registered
5th of 10
by date

Among the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by planned enrollment, is one of 3 that started in 2025, is one of 6 in phase 1, and was the 5th registered.

Heart Failure

6,334 studies on the registry are indexed under Heart Failure; 1,392 are open to participants now.

Browse Heart Failure studies →

Open to participants now

5 of the 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 966 Heart Failure studies recruiting now, 689 (71%) set no upper age limit and 89 (9%) stop at 75 or younger; 63 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Heart Failure by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic and immunogenicity of single subcutaneous injection of SHR-4658 in healthy volunteers and volunteers with elevated blood pressure.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able and willing to provide a written .
  2. Blood pressure as defined in the protocol.
  3. Male or female,aged 18 to 55 years (inclusive).
  4. Meet the weight standard.

Exclusion criteria

Exclusion Criteria:

  1. Known history or current disease.
  2. Protocol-defined risk factors for disease.
  3. Participated in clinical trials of other drugs or medical devices.
  4. Pregnant or nursing women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    SHR-4658 Group

    Drug: SHR-4658 Injection.

  • Placebo comparator
    SHR-4658 Placebo Group

    Drug: SHR-4658 Placebo Injection

Interventions

  • DrugSHR-4658 Injection.

    SHR-4658 injection.

  • DrugSHR-4658 Placebo Injection

    SHR-4658 placebo injection.

06

What researchers measure

Primary outcomes

  1. Adverse events (AEs)

    Time frame: Approximately 16 weeks.

Secondary outcomes

  1. Area under the concentration-time curve from time 0 to the last time point (AUC0-last)

    Time frame: Approximately 16 weeks.

  2. Area under the concentration-time curve from time 0 to infinity (AUC0-inf)

    Time frame: Approximately 16 weeks.

  3. Maximum observed concentration (Cmax)

    Time frame: Approximately 16 weeks.

  4. Time to maximum observed concentration (Tmax)

    Time frame: Approximately 16 weeks.

  5. Apparent clearance (CL/F)

    Time frame: Approximately 16 weeks.

  6. Apparent volume of distribution (Vd/F)

    Time frame: Approximately 16 weeks.

  7. Terminal elimination half-life (t1/2)

    Time frame: Approximately 16 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2025; primary completion for Jun 2026, 7 months later.

Of 77 industry-sponsored phase 1 interventional studies under Heart Failure, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 16. This study's planned 7 months is close to that.

Counting every sponsor, half of 131 studies reached it within 14 months; a quarter within 4 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartEst.
Nov 2025
Primary completionEst.
Jun 2026
CompletionEst.
Jul 2026
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07230145
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Nov 2025 (estimated)
Primary completion
Jun 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Nov 17, 2025

Study contacts

Miao Guo
Contact
miao.guo.mg19@hengrui.com
+86-0518-82342973
Shuai Jiang
Contact
shuai.jiang.sj5@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion